2083 Ponatinib potently inhibits the activity of mutant variants of FGFR commonly found in endometrial, lung and other cancers Monday, Apr 08, 2013, 1:00 PM - 5:00 PM
2084 Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC Monday, Apr 08, 2013, 1:00 PM - 5:00 PM
3394 Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST Tuesday, Apr 09, 2013, 8:00 AM -12:00 PM
5655 AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions Wednesday, Apr 10, 2013, 8:00 AM -12:00 PM
And a special session...
Session Title: Target Validation by Chemical Probes/Designer Chemical Probes and Phenotypic Approach to Drug Discovery Session Type: Major Symposium Session Start/End Time: Tuesday, Apr 09, 2013, 8:15 AM -10:15 AM [Timothy Clackson will describe strategies to target validated kinases with the right small molecules in a talk titled: “Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML”.]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.